
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics has demonstrated effective commercial execution, with the easing of REMS requirements expected to enhance prescriber adoption of its product, FILSPARI. The recent positive topline results from a Phase 3 bridging study in Japanese patients further solidify sparsentan's potential as a foundational therapy for IgA nephropathy, a rare kidney disorder. These developments have contributed to an accelerating sales trajectory and positive market sentiment surrounding the company’s stock.
Bears say
The negative outlook on Travere Therapeutics's stock is primarily driven by the potential for failed or inconclusive clinical trials, which poses a significant risk to the development of its lead candidate, sparsentan, for rare kidney disorders. Additionally, the company may face challenges in securing adequate funding to support its drug development pipeline, further exacerbating uncertainties surrounding its future financial stability. Recent changes within the FDA, including leadership shifts and evolving review practices, have created an environment of heightened scrutiny and investor apprehension in the biotech sector.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares